This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.

Inclusion Criteria:

• age more than 18;
• histological diagnosis of AL amyloidosis;
• measurable cardiac involvement as per current response criteria (i.e. NT-proBNP >650 ng/L);
• measurable hematologic disease (dFLC >20 mg/L);
• adequate renal function (eGFR >30 mL/min) in order to be safely administered gadolinium;
• absence of atrial fibrillation with uncontrolled heart rate;
• absence of implantable cardiac devices;
• absence of pulmonary amyloidosis histologically documented;
• plan to start anti-plasma cell chemotherapy;
• plan to assess response at the Pavia center after 6 months;
• have given written informed consent to participate.

Exclusion Criteria:

• non-AL amyloidosis;
• NYHA class IV;
• PS-ECOG >3;
• severe allergy to paramagnetic tracer;
• severe claustrophobia;
• pregnant or nursing women;